Atara Biotherapeutics Inc logo

ATRA

Atara Biotherapeutics Inc

$4.71

Earnings Summary

Revenue
$7.31Mn
Net Profits
$-88.11Mn
Net Profit Margins
-1204.61%

Highlights

Revenue:

Atara Biotherapeutics Inc’s revenue jumped 105.91% since last year same period to $7.31Mn in the Q1 2022. On a quarterly growth basis, Atara Biotherapeutics Inc has generated -3.1% fall in its revenue since last 3-months.

Net Profits:

Atara Biotherapeutics Inc’s net profit fell -12.47% since last year same period to $-88.11Mn in the Q1 2022. On a quarterly growth basis, Atara Biotherapeutics Inc has generated 5.62% jump in its net profits since last 3-months.

Net Profit Margins:

Atara Biotherapeutics Inc’s net profit margin jumped 45.38% since last year same period to -1204.61% in the Q1 2022. On a quarterly growth basis, Atara Biotherapeutics Inc has generated 2.6% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Atara Biotherapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.93
EPS Estimate Current Year
-0.93

Highlights

EPS Estimate Current Quarter:

Atara Biotherapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.93 - a 5.1% jump from last quarter’s estimates.

EPS Estimate Current Year:

Atara Biotherapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.93.

Key Ratios

Key ratios of the Atara Biotherapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.87
Return on Assets (ROA)
-0.42
Return on Equity (ROE)
-0.84
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Atara Biotherapeutics Inc’s earning per share (EPS) fell -1.16% since last year same period to -0.87 in the Q1 2022. This indicates that the Atara Biotherapeutics Inc has generated -1.16% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Atara Biotherapeutics Inc’s return on assets (ROA) stands at -0.42.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Atara Biotherapeutics Inc’s return on equity (ROE) stands at -0.84.

Dividend Per Share (DPS):

Atara Biotherapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.98
-0.87
11.22%

Company Information

Atara Biotherapeutics, Inc.(@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With its lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Its platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel® in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients' lives is its mission and it will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and its leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.

Organisation
Atara Biotherapeutics Inc
Headquarters
South San Francisco, California, US
Employees
437
Industry
Health Technology
CEO
Pascal Touchon